Antonio Cuneo

18PUBLICATIONS
112CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Mar 28, 2026
Early Ibrutinib Dose Modifications in CLL: A Post Hoc Analysis of the Real-World EVIdeNCE Study.

Stefano Molica, Potito Rosario Scalzulli, Lydia Scarfò

|Jun 13, 2025
18F-FDG PET/CT Radiomics for Predicting Therapy Response in Primary Mediastinal B-Cell Lymphoma: A Bi-Centric Pilot Study.

Fabiana Esposito, Luigi Manco, Luca Urso

|Apr 16, 2025
Venetoclax-based regimens in octogenarian patients with CLL: efficacy, safety, and comparison to BTKi in a multicenter cohort.

Andrea Serafin, Alessandro Cellini, Enrica Antonia Martino

|Mar 14, 2025
Assessing the economic burden of Waldenström's Macroglobulinemia (WM), Marginal Zone Lymphoma (MZL), and Chronic Lymphocytic Leukemia (CLL).

Matteo Scortichini, Martina Paoletti, Angela Ragonese

|Aug 10, 2024
Chronic Lymphocytic Leukemia: Prognostic Factors in the Era of Novel Drugs.

Antonio Urso, Enrica Antonia Martino, Antonio Cuneo

|Mar 28, 2024
Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study.

Francesca Romana Mauro, Potito Rosario Scalzulli, Lydia Scarfò

Pageof 3

Frequent Collaborators

5 joint publications

Gian Matteo Rigolin

5 joint publications

Luca Laurenti

4 joint publications

Francesco Albano

3 joint publications

Fabrizio Pane